254 related articles for article (PubMed ID: 34304791)
1. Medical Therapies for Diarrhea-Predominant Irritable Bowel Syndrome.
Sayuk GS
Gastroenterol Clin North Am; 2021 Sep; 50(3):611-637. PubMed ID: 34304791
[TBL] [Abstract][Full Text] [Related]
2. Treating Chronic Abdominal Pain in Patients with Chronic Abdominal Pain and/or Irritable Bowel Syndrome.
Stemboroski L; Schey R
Gastroenterol Clin North Am; 2020 Sep; 49(3):607-621. PubMed ID: 32718573
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome.
Munjal A; Dedania B; Cash BD
Expert Opin Pharmacother; 2020 Jan; 21(1):63-71. PubMed ID: 31738621
[No Abstract] [Full Text] [Related]
4. Recent advances in pharmacological treatment of irritable bowel syndrome.
Lazaraki G; Chatzimavroudis G; Katsinelos P
World J Gastroenterol; 2014 Jul; 20(27):8867-85. PubMed ID: 25083060
[TBL] [Abstract][Full Text] [Related]
5. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
7. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S
Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
9. Common Functional Gastroenterological Disorders Associated With Abdominal Pain.
Bharucha AE; Chakraborty S; Sletten CD
Mayo Clin Proc; 2016 Aug; 91(8):1118-32. PubMed ID: 27492916
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
[TBL] [Abstract][Full Text] [Related]
11. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
12. Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea.
Piovezani Ramos G; Camilleri M
Dig Dis Sci; 2023 May; 68(5):1677-1690. PubMed ID: 36376576
[TBL] [Abstract][Full Text] [Related]
13. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
14. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
15. Emerging pharmacological therapies for the irritable bowel syndrome.
Maneerattanaporn M; Chang L; Chey WD
Gastroenterol Clin North Am; 2011 Mar; 40(1):223-43. PubMed ID: 21333909
[TBL] [Abstract][Full Text] [Related]
16. Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study.
Hawrelak JA; Myers SP
J Altern Complement Med; 2010 Oct; 16(10):1065-71. PubMed ID: 20954962
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.
Shah E; Kim S; Chong K; Lembo A; Pimentel M
Am J Med; 2012 Apr; 125(4):381-93. PubMed ID: 22444104
[TBL] [Abstract][Full Text] [Related]
18. The role of loperamide in gastrointestinal disorders.
Hanauer SB
Rev Gastroenterol Disord; 2008; 8(1):15-20. PubMed ID: 18477966
[TBL] [Abstract][Full Text] [Related]
19. Management of the multiple symptoms of irritable bowel syndrome.
Simrén M; Törnblom H; Palsson OS; Whitehead WE
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):112-122. PubMed ID: 28403981
[TBL] [Abstract][Full Text] [Related]
20. [Irritable bowel treatment].
Fassov J; Fynne L; Krarup AL
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
